THE AMENDMENTS

In The Claims

1. (Previously Presented) A method of treating pain comprising administering to a subject in need thereof an effective amount of a compound of Formula III, a tautomer, or a pharmaceutically-acceptable salt, hydrate, or solvate thereof:

Formula III



wherein R_a and R_b are each independently selected from the group consisting of: hydrogen, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, and saturated or unsaturated C_{2-6} heterocycle; or

R_a and R_b are optionally taken together to form a ring of 3 to 7 members, with or without substitution, and with or without heteroatoms in place of ring carbon atoms;

R_c and R_c' are independently selected from the group consisting of: H, OR, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, saturated or unsaturated heterocycle, and -C(G)Σ; wherein G = O, S or NR_d; and

Σ = L, R_d, OR_d, or $N(R_d)_2$; except that $-NR_cR_c$' cannot be $-N(OR)_2$; and OR_d cannot be -OH;

each R_d is independently selected from the group consisting of: H, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, heteroaryl, and saturated or unsaturated C_{2-6} heterocycle; or

two R_d groups are optionally taken together to form a ring of 4 to 7 members, with or without unsaturation and with or without heteroatoms in place of ring-carbon units; or

one R_d and one of R_e or R_e' are optionally taken together to form a ring of 4 to 7 members, with or without unsaturation and with or without heteroatoms in place of ring-carbon units;

R is selected from the group consisting of: H, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, and saturated or unsaturated C_{2-6} heterocycle;

L is selected from the group consisting of: H, $-CF_3$, $-CF_2CF_3$, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated C_{2-6} heterocycle, saturated or unsaturated C_{1-6} alkoxy, aralkoxy, aryloxy, N,N-disubstituted-amino, N-substituted amino, and unsubstituted-amino;

when L is N-substituted-amino, or N,N-disubstituted-amino, each substituent of said amino group of L is selected from the group consisting of: C_{1-8} alkyl, C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, and saturated or unsaturated C_{2-6} heterocycle;

when L is N,N-disubstituted-amino, the two substituents independently selected from the group above are optionally taken together to form a ring of 3 to 7 members, wherein said formed ring thereon bears the remaining features of said selected substituents before said ring formation;

R_e = O or absent;

R_f = H, halogen, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated C_{2-6} heterocycle, -OH, saturated or unsaturated C_{1-6} alkoxy, aryloxy, -SH, C_{1-6} thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], amino, -N-substituted amino, or N,N-disubstituted amino; wherein each said substituent on said N-substituted-amino-group, or N,N-disubstituted-amino-group of R_f is independently selected from the group consisting of: C_{1-8} alkyl, C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, C_{2-6} heterocycle, -[(CO)R] and -[(CO)-NRR]; wherein each R is independently as defined above; or

when R_f is -[(CO)NRR], -[NH(CO)NRR], -[N(C_{1-8} alkyl)(CO)NRR], -[N(aryl)(CO)NRR], or [N(aralkyl)(CO)NRR], the R groups of a said -NRR unit in R_f are optionally taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units;

J = N or C, with the proviso that when J = N, then R_g is absent;

when J = C, R_g is selected from the group consisting of: -H, halogen, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, -OH, saturated or unsaturated C_{1-6} alkoxy, aryloxy, -SH, C_{1-6} thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], and -NRR; wherein each R is independently as defined above; or

when R_g is -[(CO)NRR] or -NRR, the R groups of said -NRR unit in R_g can be taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units;

X_1 is N, and

M is independently selected from the group consisting of: -H, halogen, CF_3, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated C_{2-6} heterocycle, -OH, C_{1-6} alkoxy, aralkoxy, aryloxy, -SH, C_{1-6} thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], amino, -N-substituted amino, and N,N-disubstituted amino; wherein each said substituent on said amino of M is independently selected from the group consisting of: saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated C_{2-6} heterocycle, -[(CO)R], -[(CO)O-(C_{1-8} alkyl)], and -[(CO)-NRR]; and when M is -[(CO)NRR], -[NH(CO)NRR], -[N(C_{1-8} alkyl)(CO)NRR], -[N(aryl)(CO)NRR], or -[N(aralkyl)(CO)NRR], the R groups of any said -NRR unit in M are optionally taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units.

2-3. (Cancelled)

4. (Currently Amended) The method according to Claim [[3]] 1, wherein said compound is selected from the group consisting of: 6-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 5-Chloro-6-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 6-Chloro-2-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-5-fluoro-nicotinic acid; 6-Chloro-2-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-5-

fluoro-nicotinic acid; 2-[6-[6-(3-Phenyl-ureido)-purin-9-yl]-2-(2-trifluoromethyl-phenyl)-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy]-nicotinic acid; 2-{2-Phenyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Biphenyl-3-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Naphthalen-2-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Benzo[*b*]thiophen-3-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Hexyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxo-spiroindan-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenylethynyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-(2-Bromo-phenyl)-6-[6-(3-ethyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-phenethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2,2-(3,4-Dihydro-1H-naphthalen)-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-p-tolyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Biphenyl-4-yl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-(4-Acetylamino-phenyl)-6-[6-(3-cyclopentyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; and 2-{2-tert-Butyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid.

5. (Previously Presented) A method of treating pain comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a compound of Formula IV, a tautomer, or a pharmaceutically acceptable salt, hydrate, or solvate thereof,

Formula IV



wherein R_a, R_b, R_c, R_c', Σ, R, L, R_d, R_e, R_f, J, R_g are as defined in Formula I of Claim I;
M' is selected from the group consisting of: -H, halogen, CF_3, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated C_{2-6} heterocycle, -OH, C_{1-6} alkoxy, aralkoxy, aryloxy, -SH, C_{1-6} thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], amino, -N-substituted amino, and N,N-disubstituted amino; wherein each said substituent on said amino of M is independently selected from the group consisting of: saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated C_{2-6} heterocycle, -[(CO)R], -[(CO)O-(C_{1-8} alkyl)], and -[(CO)-NRR]; and when M' is -[(CO)NRR], -[NH(CO)NRR], -[N(C_{1-8} alkyl)(CO)NRR], -[N(aryl)(CO)NRR], or -[N(aralkyl)(CO)NRR], the R groups of any said -NRR unit in M' are optionally taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units;
the M' and -CO_2R groups are independently attached to any carbon of the pyrrolidine ring; and
M' is not a halogen, hydroxy, sulfhydryl, or amino group when M' is attached to a carbon that is bonded to the pyrollidine nitrogen atom at the alpha position.

6. (Original) The method according to Claim 5, wherein said compound is selected from the group consisting of: 1-{2-Phenyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-

d][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Phenyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Benzyl-6-[6-(3-ethyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-(2-Phenyl-6-{6-[3-(2-phenyl-cyclopropyl)-ureido]-purin-9-yl}-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl)-pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-Benzyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Benzo[*b*]thiophen-3-yl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Benzyl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-naphthalen-2-yl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-Hexyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; and 1-(3-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl}-propionyl)-pyrrolidine-2-carboxylic acid.

7. (Cancelled)

8. (Previously Presented) The method according to Claim 1, wherein said pain is traumatic pain, neuropathic pain, organ pain, or pain associated with diseases.

9. (Original) The method according to Claim 8, wherein said traumatic pain is pain resulting from injury, burn, post-surgical pain or inflammatory pain.

10. (Original) The method according to Claim 8, wherein said organ pain is ocular, corneal, bone, heart, skin, visceral, joint, dental or muscle pain.

11. (Original) The method according to Claim 8, wherein said diseases are cancer, AIDS, arthritis, herpes, sickle cell anemia or migraine.

12. (Previously Presented) The method according to Claim 1, wherein said pharmaceutical composition is administered topically to said subject.

13. (Previously Presented) The method according to Claim 1, wherein said pharmaceutical composition is administered via injection to said subject.

14. (Previously Presented) The method according to Claim 1, wherein said pharmaceutical composition is administered orally to said subject.

15. (Previously Presented) The method according to Claim 1, wherein said pharmaceutical composition is administered by intranasal administration to said subject.

16. (Previously Presented) The method according to Claim 1, wherein said pharmaceutical composition is administered to said subject in an inhaleable form.

17. (Previously Presented) The method according to Claim 1, wherein said compound is included in a pharmaceutical composition.

18. (Previously Presented) The method according to Claim 4, wherein said compound is selected from the group consisting of: 2-[6-[6-(3-Phenyl-ureido)-purin-9-yl]-2-(2-trifluoromethyl-phenyl)-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy]-nicotinic acid; 2-{2-Phenyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Biphenyl-3-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Naphthalen-2-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Benzo[*b*]thiophen-3-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Hexyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxo-spiroindan-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-

yl]-2-phenethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenylethynyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-(2-Bromo-phenyl)-6-[6-(3-ethyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-phenethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2,2-(3,4-Dihydro-1H-naphthalen)-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-p-tolyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Biphenyl-4-yl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-(4-Acetylamino-phenyl)-6-[6-(3-cyclopentyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; and 2-{2-tert-Butyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid.

19. (Previously Presented) The method according to Claim 4, wherein said compound is 2-{2-Biphenyl-4-yl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethoxy}-nicotinic acid.

20. (New) The method according to Claim 1, wherein R_c and R_c' are independently selected from the group consisting of: H, OR, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, and saturated or unsaturated heterocycle.

21. (New) The method according to Claim 20, wherein R_a and R_b are independently selected from the group consisting of: hydrogen, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, and saturated or unsaturated C_{2-6} heterocycle.

22. (New) The method according to Claim 5, wherein R_c and R_c' are independently selected from the group consisting of: H, OR, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, and saturated or unsaturated heterocycle.

23. (New) The method according to Claim 22, wherein R_a and R_b are independently selected from the group consisting of: hydrogen, saturated or unsaturated C_{1-8} alkyl, saturated or unsaturated C_{3-7} cycloalkyl, aralkyl, aryl, and saturated or unsaturated C_{2-6} heterocycle.